ESC 365 - The effect of atorvastatin on mevalonate levels in blood plasma in patients with coronary heart disease and muscle side effects

Open Access

The effect of atorvastatin on mevalonate levels in blood plasma in patients with coronary heart disease and muscle side effects

Session: Advances in risk stratification and lipid management

Topic: Drug therapy

Speaker: Mrs T. Lauritzen (Drammen, NO)

Event: ESC Preventive Cardiology 2024

Congress Presentation

Add to my library

About the speaker

Mrs Trine Lauritzen

Drammen Hospital, Drammen (Norway)

0 follower

6 more presentations in this session

Unlinking sudden death from coronary artery disease - a systematic scoping review of the association of low-density lipoprotein cholesterol and sudden death

Speaker: Ms R. Beyer (Berlin, DE)

The association between the remnant cholesterol and non-HDL-C with subclinical carotid atherosclerosis in patients with metabolic syndrome

Speaker: Professor I. Tasic (Niska Banja, RS)

A polyphenol-rich active substance (TOTUM-070) lowers LDL-cholesterol in subjects with moderate hypercholesterolemia. The OLALIP study

Speaker: Doctor Y. Otero (Perigny, FR)

Lipoprotein(a) and referrals to a specialist lipid clinic

Speaker: Doctor C. Kennedy (Dublin, IE)

Lp(a) and vascular inflammation: data from perivascular fat attenuation index measurements

Speaker: Doctor S. Simantiris (Athens, GR)

Access the full session

Advances in risk stratification and lipid management

Speakers: Mrs T. Lauritzen, Ms R. Beyer, Professor I. Tasic, Doctor Y. Otero, Doctor C. Kennedy...

About the event

ESC Preventive Cardiology 2024

25 April - 27 April 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources